MedTrace Logo

Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery

NCT00353964 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2006-07-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of three concentrations of rEV131, a new investigational anti-inflammatory agent, compared to placebo (an inactive substance) and an FDA approved anti-inflammatory agent in patients with ocular inflammation who have undergone cataract extraction with intra-ocular lens implantation.

Conditions

  • Ocular Inflammation

Interventions

DRUG

rEV131

DRUG

Prenisolone sodium phosphate 1.0%

DRUG

rEV131 vehicle

Sponsors & Collaborators

  • Evolutec Group

    lead INDUSTRY

Principal Investigators

  • Wynne Weston-Davies, MD · Evolutec Group

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00353964 on ClinicalTrials.gov